SCHEMBL6444231

SCHEMBL6444231

Nc1nc(=O)c2nc(CCl)cnc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 4/20 0.40
KDM4E B2RXH2 3/20 0.37
ALDH1A1 P00352 3/20 0.37
HSD17B10 Q99714 3/20 0.37
LMNA P02545 1/20 0.37
GLA P06280 1/20 0.37
PMP22 Q01453 1/20 0.37
HIF1A Q16665 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 2/20 0.31
HPGD P15428 2/20 0.31
KMT2A Q03164 2/20 0.31
BACE1 P56817 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31
AKR1B1 P15121 6/20 0.31
TYMS P04818 1/20 0.30
POLB P06746 1/20 0.30
GAA P10253 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4816470 0.88 KDM4E (0.44) NOS1KDM4EALDH1A1HSD17B10LMNA
SCHEMBL14403234 0.86 NOS1 (0.40) NOS1KDM4EALDH1A1HSD17B10LMNA
SCHEMBL3631374 0.84 NOS1 (0.40) NOS1KDM4EALDH1A1HSD17B10LMNA
SCHEMBL1981722 0.84 ALDH1A1 (0.41) NOS1KDM4EALDH1A1HSD17B10LMNA
Bromide SCHEMBL3573044 0.83 NOS1 (0.39) NOS1KDM4EALDH1A1HSD17B10LMNA
SCHEMBL3526052 0.79 KDM4E (0.40) NOS1KDM4EALDH1A1HSD17B10LMNA
SCHEMBL3528804 0.76 MAPK1 (0.41) NOS1KDM4EALDH1A1HSD17B10LMNA
SCHEMBL22497884 0.76 ALDH1A1 (0.40) NOS1KDM4EALDH1A1HSD17B10LMNA
SCHEMBL3528784 0.76 ALDH1A1 (0.40) NOS1KDM4EALDH1A1HSD17B10LMNA
SCHEMBL853172 0.76 ALDH1A1 (0.40) NOS1KDM4EALDH1A1HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1432713-A4 FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS ESSENTIAL THERAPEUTICS INC (US) 2005-05-11 EP disclosed
EP-1432713-A2 FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS Essential Therapeutics, Inc. (US) 2004-06-30 EP disclosed
US-20030176436-A1 Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof ALA PAUL J (DE) 2003-09-18 US disclosed
WO-2003002064-A2 FUSED PYRIMIDINE DHFR INHIBITORS AS ANTIBACTERIALS ESSENTIAL THERAPEUTICS, INC. (US) 2003-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176436-A1 Novel heterocyclic compounds as selective bacterial DHFR inhibitors and their uses thereof DHFR, DHODH, DPYD NOS1 1340/4885KDM4E 1009/4885ALDH1A1 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.